Clinical Trial Update: Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating EPI-003 in nucleoside analogue-treated patients with chronic hepatitis B; the trial is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• EPI-003

Snippet

Sponsor: Epigenic Therapeutics, Inc | Conditions: Chronic Hepatitis B, HBV (Hepatitis B Virus) | Phase 1 | Status: NOT_YET_RECRUITING